Summit Therapeutics Inc. (SMMT) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
601 Brickell Key Drive
Miami, FL 33131
United States of America (the)
Phone
617 514 7149
Website
Sector
Healthcare
Industry
Biotechnology
Employees
265
First IPO Date
March 05, 2015
| Name | Title | Pay | Year Born |
| Robert W. Duggan | Co-CEO & Executive Chairman | 172,376 | 1945 |
| Mahkam Zanganeh | Co-CEO, President & Director | 1.03M | 1970 |
| Manmeet Singh Soni | Chief Operating Officer, Chief Financial Officer & Director | 1.03M | 1978 |
| Allen S. Yang | Head of R&D Strategy | 0 | 1968 |
| Howard Jack West | Vice President of Clinical Development | 0 | N/A |
| Laura Q. Chow | Senior Vice President of Clinical Development | 0 | N/A |
| Urte Gayko | Chief Regulatory, Quality & Pharmacovigilance Officer | 0 | 1971 |
| Dave Gancarz | Chief Business & Strategy Officer | 0 | N/A |
| Kay Elizabeth Davies | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor | 0 | 1951 |
| Bilal Piperdi | Chief Medical Officer | 0 | N/A |
| Elaine Carla Stracker | Chief Legal Officer | 0 | 1961 |
| Nathan LiaBraaten | Senior Director of Investor Relations | 0 | N/A |
| Bhaskar Anand | Chief Accounting Officer & Head of Finance | 0 | 1978 |
| Wang Clow Fong | Chief Biometrics Officer | 0 | 1958 |
| Robert LaCaze | Chief Commercial Officer | 0 | N/A |
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.